Zoetis has been granted a patent for cyclic depsipeptides that can be used to treat endoparasitic infections in animals. The patent covers the compound of Formula (3A) and its veterinary acceptable salts, as well as compositions and methods of treatment using this compound. GlobalData’s report on Zoetis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Zoetis, Personalized cancer vaccines was a key innovation area identified from patents. Zoetis's grant share as of September 2023 was 54%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11771738B2) discloses a compound of Formula (3A) and its various applications in the field of veterinary medicine. The compound, along with its stereoisomers and veterinary acceptable salts, is claimed to have therapeutic potential in treating parasitic infections in animals.
The compound described in claim 1 of the patent is a complex molecule with a specific chemical structure. The subsequent claims specify the different variations of the compound, including the selection of different rings and substituents. These variations are claimed to have veterinary applications and can be used to treat parasitic infections in animals.
The patent also claims compositions comprising the compound, its stereoisomers, and veterinary acceptable salts, along with
To know more about GlobalData’s detailed insights on Zoetis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.